You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,900,582

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,900,582

Title:	Deimmunized anti c-Met humanized antibodies and uses thereof
Abstract:	A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer.
Inventor(s):	Cheong; Kwang-ho (Seoul, KR), Lee; Seung-hyun (Suwon-si, KR)
Assignee:	Samsung Electronics Co., Ltd. (Suwon-Si, KR)
Application Number:	13/725,125
Patent Claims:	1. An anti c-Met humanized antibody comprising a heavy chain variable region comprising any one of SEQ ID NOs: 1-5, and a light chain variable region comprising any one of SEQ ID NOs: 6-9. 2. The anti c-Met humanized antibody of claim 1, wherein the heavy chain variable region comprises SEQ ID NO: 2 and the light chain variable region comprises SEQ ID NO: 7. 3. The anti c-Met humanized antibody of claim 1, wherein the heavy chain variable region comprising SEQ ID NO: 2, and the light chain variable region comprises SEQ ID NO: 9. 4. The anti c-Met humanized antibody of claim 1, wherein the heavy chain variable region comprises SEQ ID NO: 5 and the light chain variable region comprises SEQ ID NO: 7. 5. The anti c-Met humanized antibody of claim 1, wherein the antibody specifically binds c-Met from a human or monkey, a mouse, or a rat. 6. The anti c-Met humanized antibody of claim 1, wherein the anti c-Met humanized antibody is a monoclonal antibody. 7. The anti c-Met humanized antibody of claim 1, wherein the anti c-Met humanized antibody is less immunogenic than trastuzumab. 8. The anti c-Met humanized antibody of claim 1, wherein the anti c-Met humanized antibody is an antigen binding fragment selected from the group consisting of scFv, (scFv).sub.2, Fab, Fab' and F(ab').sub.2. 9. A pharmaceutical composition comprising an anti c-Met humanized antibody of claim 1 and a pharmaceutically acceptable support, diluent, or excipient. 10. The pharmaceutical composition of claim 9, wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 7. 11. The pharmaceutical composition of claim 9, wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 9. 12. The pharmaceutical composition of claim 9, wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 7.

Details for Patent 8,900,582

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2031-12-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2031-12-22
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2031-12-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.